TY - JOUR
T1 - Analysis of complex biomarkers for human immune-mediated disorders based on cytokine responsiveness of peripheral blood cells
AU - Davis, John M.
AU - Knutson, Keith L.
AU - Strausbauch, Michael A.
AU - Crowson, Cynthia S.
AU - Therneau, Terry M.
AU - Wettstein, Peter J.
AU - Matteson, Eric L.
AU - Gabriel, Sherine E.
PY - 2010/6/15
Y1 - 2010/6/15
N2 - The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.
AB - The advent of improved biomarkers promises to enhance the clinical care for patients with rheumatoid arthritis (RA) and other immune-mediated disorders. We have developed an innovative approach to broadly assess the cytokine responsiveness of human PBMCs using a multistimulant panel and multiplexed immunoassays. The objective of this study was to demonstrate this concept by determining whether cytokine profiles could discriminate RApatients according to disease stage (early versus late) or severity. A 10-cytokine profile, consisting of IL-12, CCL4, TNF-α, IL-4, and IL-10 release in response to stimulation with anti-CD3/anti-CD28, CXCL8 and IL-6 in response to CMVand EBV lysate, and IL-17A, GM-CSF, and CCL2 in response to human heat shock protein 60, easily discriminated the early RA group from controls. These data were used to create an immune response score, which performed well in distinguishing the early RA patients from controls and also correlated with several markers of disease severity among the patients with late RA. In contrast, the same 10-cytokine profile assessed in serum was far less effective in discriminating the groups. Thus, our approach lays the foundation for the development of immunologic "signatures" that could be useful in predicting disease course and monitoring the outcomes of therapy among patients with immune-mediated diseases.
UR - http://www.scopus.com/inward/record.url?scp=77953624350&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953624350&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.0904180
DO - 10.4049/jimmunol.0904180
M3 - Article
C2 - 20495063
AN - SCOPUS:77953624350
SN - 0022-1767
VL - 184
SP - 7297
EP - 7304
JO - Journal of Immunology
JF - Journal of Immunology
IS - 12
ER -